Global
  • About Us
    Company Profile
    Milestones
    Core Team
  • Science and Technology
    Research Field
    Technology Platform
    Product Pipeline
    Manufacturing Plants
    Intellectual Property Rights
  • Investor Relations
    Company Information
    Financial Reports
    Announcements and Circulars
    Corporate Governance
  • News Centre
    Company News
    Media Coverage
  • Join Us
    Corporate Culture
    Business Outlook
    Benefits
    Job Opportunities
  • Contact us
    Shanghai
    Beijing
    Overseas
NEWS CENTRE NEWS CENTRE
NEWS CENTRE
News Centre
Company News Media Coverage

Year

2023
2022
2021
2020
2019
2018

Month

01
02
03
04
05
06
07
08
09
10
11
12
2022-07-25 16:12
An exclusive interview with Professor Huang Jing | Pucotenlimab has been approved, which brings a new treatment option for MSI-H/dMMR advanced solid tumors!
Introduction: The incidence of microsatellite instability-high (MSI-H) or mismatch repair deficiency (dMMR) in patients with solid tumors is approximately 10%-22% [1], with a higher incidence for c...
More
  • The First Domestic TF ADC Drug Approved for Clinical Use: LEPU BIOPHARMA MRG004A
    2021-08-05 09:08
    The First Domestic TF ADC Drug Approved for Clinical Use: LEPU BIOPHARMA MRG004A
    More
  • MRG003 Hopefully Reshape the Therapeutic Landscape of Advanced NSCLC
    2021-07-22 10:01
    MRG003 Hopefully Reshape the Therapeutic Landscape of Advanced NSCLC
    More
  • LEPU BIOPHARMA Conducting a Clinical Trial of MRG002, Bringing New Hopes for HER2-positive Breast Cancer Patients
    2021-07-19 17:42
    LEPU BIOPHARMA Conducting a Clinical Trial of MRG002, Bringing New Hopes for HER2-positive Breast Cancer Patients
    More
  • Lepu’s NDA for anti-PD-1 antibody accepted ahead of Hong Kong IPO
    2021-07-15 15:04
    Lepu’s NDA for anti-PD-1 antibody accepted ahead of Hong Kong IPO
    More
  • The NDA for Pucotenlimab (HX008) of LEPU BIOPHARMA as the second-line treatment for melanoma was formally accepted by the CDE
    2021-07-05 11:46
    The NDA for Pucotenlimab (HX008) of LEPU BIOPHARMA as the second-line treatment for melanoma was formally accepted by the CDE
    More
  • At the ASCO meeting in 2021, Lepu Biopharma reported on the progress of two clinical studies of HX008.
    2021-06-07 15:12
    At the ASCO meeting in 2021, Lepu Biopharma reported on the progress of two clinical studies of HX008.
    More
<1>
Home Page
Company Profile
Strategic Investors
Technical Strength
News Centre
About Us
Company Profile
Milestones
Core Team
Science and Technology
Research Field
Technology Platform
Product Pipeline
Manufacturing Plants
Intellectual Property Rights
Investor Relations
Company Information
Financial Reports
Announcements and Circulars
Corporate Governance
News Centre
Company News
Media Coverage
Join Us
Corporate Culture
Business Outlook
Benefits
Job Opportunities
Contact us
Copyright 2021 By Lepu Biopharma CO.,Ltd.
京公网安备11011702000459号京ICP备20018649号-1

Home Page
About Us
Science and Technology
Strategic Investors
News Centre
Join Us
Contact Us